Picture of Bionexus Gene Lab logo

BGLC — Bionexus Gene Lab Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-15.24%
3m-15.57%
6m-20.8%
1yr-22.3%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-46.22%
50d MA-23.89%
200d MA-28.88%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value29.06
Price to Tang. Book29.06
Price to Free Cashflown/a
Price to Sales16.01
EV to EBITDA242.67

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital10.23%
Return on Equity6.18%
Operating Margin5.68%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Bionexus Gene Lab EPS forecast chart

Profile Summary

BioNexus Gene Lab Corp. is an emerging molecular diagnostics company. The Company is focused on the application of functional genomics to enable early diagnosis and personalized health management. The Company's wholly owned subsidiaries include Bionexus Gene Lab Sdn. Bhd. (Bionexus Malaysia) and Chemrex Sdn. Bhd. (Chemrex). BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which it uses in its business. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. These diseases include cancers, bowel diseases and osteoarthritis. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asia Pacific region.

Directors

    Last Annual
    December 31st, 2021
    Last Interim
    March 31st, 2022
    Incorporated
    May 12th, 2017
    Public Since
    February 21st, 2020
    No. of Shareholders
    319
    No. of Employees
    8
    Sector
    Healthcare Providers & Services
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq
    Shares in Issue
    171,218,152

    BGLC Share Price Performance

    Similar to BGLC

    Picture of 4Cable TV International logo

    4Cable TV International

    us flag iconPink Sheets on Nasdaq

    Picture of Abattis Bioceuticals logo

    Abattis Bioceuticals

    us flag iconPink Sheets on Nasdaq

    Picture of Accelera Innovations logo

    Accelera Innovations

    us flag iconPink Sheets on Nasdaq

    Picture of ACI Global logo

    ACI Global

    us flag iconPink Sheets on Nasdaq

    Picture of Quantum Medical Transport logo

    Quantum Medical Transport

    us flag iconPink Sheets on Nasdaq

    FAQ

    Or unlock with your email

    Or unlock with your email